Date | Title | In Focus | Federal Register | FDA Link |
3 January 2013 | Draft Revision of Guidance for Industry on Providing Regulatory Submissions in Electronic Format-Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications | |||
4 January 2013 | Advisory Committee for Reproductive Health Drugs | |||
4 January 2013 | Medical Imaging Drugs Advisory Committee | |||
4 January 2013 | Availability of Safety and Effectiveness Summaries for Premarket Approval Applications | |||
4 January 2013 | Accessible Medical Device Labeling in a Standard Content and Format | |||
4 January 2013 | Guidance on Medical Devices: The Pre-Submission Program and Meetings With FDA Staff; Withdrawal | |||
7 January 2013 | Anesthesiology Devices; Reclassification of Membrane Lung for Long-Term Pulmonary Support; Redesignation as Extracorporeal Circuit and Accessories for Long-Term Pulmonary/Cardiac Support | |||
7 January 2013 | Cardiovascular Devices; Reclassification of External Cardiac Compressor | |||
9 January 2013 | Privacy Act, Exempt Record System; Withdrawal | |||
9 January 2013 | Privacy Act, Exempt Record System; Withdrawal | |||
10 January 2013 | Dental Devices; Reclassification of Blade-Form Endosseous Dental Implant | |||
10 January 2013 | Draft Guidance for Industry on Abuse-Deterrent Opioids-Evaluation and Labeling | |||
10 January 2013 | Blood Products Advisory Committee | |||
10 January 2013 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | |||
13 January 2013 | Modifications to the List of Recognized Standards, Recognition List Number: 030 | |||
13 January 2013 | Creating an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need | |||
16 January 2013 | Electronic Submission of Food and Drug Administration Adverse Event Reports and Other Safety Information Using the Electronic Submission Gateway and the Safety Reporting Portal | |||
17 January 2013 | Generic Drug User Fee-Active Pharmaceutical Ingredient and Finished Dosage Form Facility Fee Rates for Fiscal Year 2013 | |||
18 January 2013 | Effective Date of Requirement for Premarket Approval for Two Class III Preamendments Devices | |||
18 January 2013 | Notification Procedures for Statements on Dietary Supplements | |||
22 January 2013 | Current Good Manufacturing Practice Requirements for Combination Products | |||
22 January 2013 | Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 | |||
22 January 2013 | Draft Guidance for Industry and Food and Drug Administration Staff; Submissions for Postapproval Modifications to a Combination Product Approved Under Certain Marketing Applications | |||
22 January 2013 | Electronic Submission Process for Requesting Export Certificates From the Center for Devices and Radiological Health | |||
24 January 2013 | Guidance for Industry and Food and Drug Administration Staff; Humanitarian Use Device (HUD) Designations | |||
24 January 2013 | Clinical Flow Cytometry in Hematologic Malignancies | |||
25 January 2013 | Ophthalmic Devices; Classification of the Scleral Plug | |||
25 January 2013 | Antimicrobial Animal Drug Distribution Reports Under Section 105 of the Animal Drug User Fee Amendments of 2008 | |||
25 January 2013 | Vaccines and Related Biological Products Advisory Committee | |||
28 January 2013 | New Animal Drugs; Cefpodoxime; Meloxicam | |||
28 January 2013 | 2013 Assuring Radiation Protection | |||
28 January 2013 | Electronic Study Data Submission; Data Standard Support End Date | |||
28 January 2013 | Guidance for Industry on Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling | |||
28 January 2013 | Detecting and Evaluating Drug-Induced Liver Injury; What's Normal, What's Not, and What Should We Do About It? | |||
29 January 2013 | Statement of Organization, Functions, and Delegations of Authority | |||
30 January 2013 | Science Board to the Food and Drug Administration | |||
31 January 2013 | Guidance for Industry, FDA Staff, and Foreign Governments: Fiscal Year 2012 Medical Device User Fee Small Business Qualification and Certification | |||
31 January 2013 | Medical Devices; Inspection by Accredited Persons Program | |||
31 January 2013 | Determination That DIFFERIN (Adapalene) Solution, 0.1%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | |||
31 January 2013 | Considerations Regarding Food and Drug Administration Review and Regulation of Drugs for the Treatment of Amyotrophic Lateral Sclerosis | |||
31 January 2013 | Accessible Medical Device Labeling in a Standard Content and Format Public Workshop; Request for Comments; Correction | |||
31 January 2013 | Determination of Regulatory Review Period for Purposes of Patent Extension; BEYAZ | |||
31 January 2013 | Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI | |||
4 February 2013 | International Conference on Harmonisation; Draft Guidance on S10 Photosafety Evaluation of Pharmaceuticals | |||
4 February 2013 | Draft Guidance for Industry on Enrichment Strategies for Clinical Trials To Support Approval of Human Drugs and Biological Products; Extension of Comment Period | |||
6 February 2013 | Center for Drug Evaluation and Research; Prescription Drug Labeling Improvement and Enhancement Initiative | |||
6 February 2013 | Training Program for Regulatory Project Managers | |||
6 February 2013 | Medical Device User Fee Cover Sheet, Form FDA 3601 | |||
6 February 2013 | Administrative Detention and Banned Medical Devices | |||
7 February 2013 | Dental Devices; Reclassification of Temporary Mandibular Condyle Prosthesis | |||
7 February 2013 | Request for Nominations for Voting Members on Public Advisory Panels or Committees | |||
8 February 2013 | Medical Devices; Ophthalmic Devices; Classification of the Eyelid Weight | |||
8 February 2013 | Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens That Are Not Individually Identifiable | |||
8 February 2013 | Draft Guidance for Industry on Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease | |||
8 February 2013 | International Drug Scheduling; Convention on Psychotropic Substances; World Health Organization Scheduling Recommendations for Gamma-hydroxybutyric Acid | |||
11 February 2013 | Draft Guidance for Industry on Immunogenicity Assessment for Therapeutic Protein Products | |||
11 February 2013 | Food and Drug Administration/Xavier University PharmaLink Conference-Quality in a Global Supply Chain | |||
12 February 2013 | Food and Drug Administration Drug Shortages Task Force and Strategic Plan | |||
13 February 2013 | Guidance for Industry and Food and Drug Administration Staff; Center for Devices and Radiological Health Appeals Processes | |||
13 February 2013 | Documents To Support Submission of an Electronic Common Technical Document | |||
13 February 2013 | Annual Computational Science Symposium; Conference | |||
13 February 2013 | Global Quality Systems-An Integrated Approach To Improving Medical Product Safety | |||
15 February 2013 | Draft Guidance for Industry, Food and Drug Administration Staff, and Third Party Reviewers: Accreditation and Reaccreditation Process for Firms Under the Third Party Review Program: Part I | |||
15 February 2013 | Guidance for Industry and Food and Drug Administration Staff: Clinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation | |||
15 February 2013 | Circulatory System Devices Panel of the Medical Devices Advisory Committee | |||
15 February 2013 | Transmissible Spongiform Encephalopathies Advisory Committee | |||
19 February 2013 | Medical Devices; Pediatric Uses of Devices; Requirement for Submission of Information on Pediatric Subpopulations That Suffer From a Disease or Condition That a Device Is Intended To Treat, Diagnose, or Cure | |||
19 February 2013 | Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Act | |||
19 February 2013 | Draft Guidance for Industry and Food and Drug Administration Staff; Providing Information About Pediatric Uses of Medical Devices Under Section 515A of the Federal Food, Drug, and Cosmetic Act | |||
19 February 2013 | Neonatal Subcommittee of the Pediatric Advisory Committee | |||
20 February 2013 | Environmental Impact Considerations | |||
21 February 2013 | Extreme Weather Effects on Medical Device Safety and Quality | |||
21 February 2013 | Device Good Manufacturing Practice Advisory Committee | |||
22 February 2013 | Draft Guidance for Industry and Food and Drug Administration Staff: Distinguishing Medical Device Recalls From Product Enhancements; Reporting Requirements | |||
22 February 2013 | Determination of Regulatory Review Period for Purposes of Patent Extension; Sapien Transcatheter Heart Valve | |||
22 February 2013 | Request for Nominations for Voting and/or Nonvoting Consumer Representatives on Public Advisory Committees or Panels and Request for Notification From Consumer Organizations Interested in Participating in the Selection Process for Nominations for Voting and/or Nonvoting Consumer Representatives on Public Advisory Committees or Panels | |||
25 February 2013 | Fecal Microbiota for Transplantation | |||
25 February 2013 | Pediatric Advisory Committee | |||
25 February 2013 | Joint Meeting of the Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee | |||
25 February 2013 | Guidance for Industry: Guidance on the Labeling of Certain Uses of Lecithin Derived From Soy Under Section 403(w) of the Federal Food, Drug, and Cosmetic Act; Withdrawal of Guidance | |||
25 February 2013 | Guidance for Industry on Labeling for Human Prescription Drug and Biological Products-Implementing the Physician Labeling Rule Content and Format Requirements | |||
25 February 2013 | Draft Guidance for Industry on Attachment to Guidance on Antiviral Product Development-Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting Hepatitis C Virus Resistance Data | |||
25 February 2013 | Human Subject Protection; Acceptance of Data From Clinical Studies for Medical Devices | |||
26 February 2013 | Additional Safeguards for Children in Clinical Investigations of Food and Drug Administration-Regulated Products | |||
26 February 2013 | Foreign Clinical Studies Not Conducted Under an Investigational New Drug Application | |||
26 February 2013 | Draft Guidance for Industry: Recommendations for Screening, Testing, and, Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis | |||
26 February 2013 | Guidance for Clinical Investigators, Industry, and Food and Drug Administration Staff: Financial Disclosure by Clinical Investigators | |||
26 February 2013 | Guidance for Industry: Implementation of an Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma | |||
26 February 2013 | Seventh Annual Drug Information Association/Food and Drug Administration Statistics Forum-2013 | |||
27 February 2013 | Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee | |||
27 February 2013 | Oncologic Drugs Advisory Committee | |||
27 February 2013 | Ophthalmic Devices Panel of the Medical Devices Advisory Committee | |||
27 February 2013 | Psychopharmacologic Drugs Advisory Committee | |||
27 February 2013 | Science Board to the Food and Drug Administration Advisory Committee; Amendment of Notice | |||
28 February 2013 | Draft Guidance for Industry and Review Staff on Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling | |||
28 February 2013 | Mammography Quality Standards Act Requirements | |||
28 February 2013 | Determination of Regulatory Review Period for Purposes of Patent Extension; LAVIV | |||
28 February 2013 | Determination of Regulatory Review Period for Purposes of Patent Extension; ZYTIGA | |||
4 March 2013 | Pulse Oximeters-Premarket Notification Submissions [510(k)s]; Guidance for Industry and Food and Drug Administration Staff | |||
4 March 2013 | Medical Devices; Exemption From Premarket Notification; Class II Devices; Powered Patient Transport | |||
4 March 2013 | Medical Devices; Exemption From Premarket Notification; Class II Devices; Wheelchair Elevator | |||
4 March 2013 | Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness | |||
5 March 2913 | Draft Guidance for Industry and Food and Drug Administration Staff; Types of Communication During the Review of Medical Device Submissions | |||
5 March 2913 | International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Draft Revised Guidance for Industry on "Studies To Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing" (VICH GL23(R)) | |||
5 March 2913 | International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Revised Guidance for Industry on "Studies To Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach To Establish a Microbiological Acceptable Daily Intake (ADI)" (VICH GL36(R)) | |||
6 March 2013 | Implementation of the FDA Food Safety Modernization Act Provision Requiring FDA To Establish Pilot Projects and Submit a Report to Congress for the Improvement of Tracking and Tracing of Food; | |||
6 March 2013 | Cheng Yi Liang: Debarment Order | |||
6 March 2013 | Guidance for Industry and Food and Drug Administration Staff: Investigational Device Exemption Guidance for Retinal Prostheses | |||
7 March 2013 | New Animal Drug Applications; Alfaprostol; Bicyclohexylammonium Fumagillin; N | |||
7 March 2013 | Veterinary Oversight of Antimicrobial Use in Livestock: Impact on Stakeholders | |||
7 March 2013 | Ag-Mark, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications | |||
8 March 2013 | Guidance for Industry: What You Need To Know About Administrative Detention of Foods; Small Entity Compliance Guide | |||
8 March 2013 | Food and Drug Administration Prescription Drug User Fee Act V Benefit-Risk Plan | |||
11 March 2013 | Draft Guidance for Industry and Food and Drug Administration Staff: Recommendations for Labeling Medical Products To Inform Users That the Product or Product Container Is Not Made With Natural Rubber Latex | |||
11 March 2013 | Drug Development for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis | |||
12 March 2013 | Cellular, Tissue and Gene Therapies Advisory Committee | |||
13 March 2013 | Guidance on Reagents for Detection of Specific Novel Influenza A Viruses | |||
13 March 2013 | Cooperative Agreement To Support Regulatory Research Related to Food and Drug Administration Commitments Under the 2012 Prescription Drug User Fee Act | |||
13 March 2013 | Draft Guidance for Industry and Review Staff on Formal Dispute Resolution: Appeals Above the Division Level | |||
13 March 2013 | Guidance for Industry on Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation | |||
13 March 2013 | Food and Drug Administration/Xavier University Global Medical Device Conference | |||
14 March 2013 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee | |||
15 March 2013 | Institutional Review Boards; Correcting Amendments | |||
15 March 2013 | Application of Advances in Nucleic Acid and Protein Based Detection Methods to Multiplex Detection of Transfusion-Transmissible Agents and Blood Cell Antigens in Blood Donations | |||
18 March 2013 | Draft Guidance for Industry and FDA Staff; Total Product Life Cycle: Infusion Pump-Premarket Notification [510(k)] Submissions | |||
18 March 2013 | Center for Drug Evaluation and Research Medical Policy Council | |||
18 March 2013 | International Conference on Harmonisation; Proposed Change to Rodent Carcinogenicity Testing of Pharmaceuticals | |||
18 March 2013 | General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee | |||
18 March 2013 | Impax Laboratories, Inc.; Withdrawal of Approval of Bupropion Hydrochloride Extended-Release Tablets, 300 Milligrams | |||
20 March 2013 | Public Hearing Before a Public Advisory Committee; Technical Amendments | |||
20 March 2013 | Current Good Manufacturing Practice for Positron Emission Tomography Drugs | |||
21 March 2013 | Pulmonary-Allergy Drugs Advisory Committee | |||
21 March 2013 | Risk Communications Advisory Committee | |||
21 March 2013 | Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications | |||
22 March 2013 | New Animal Drugs; Changes of Sponsor | |||
22 March 2013 | Provisions of the Food and Drug Administration Safety and Innovation Act Related to Medical Gases | |||
25 March 2013 | New Animal Drug Approvals; Change of Sponsor; Change of Sponsor's Drug Labeler Code; Gonadorelin Acetate; Isoflurane; Praziquantel; Propofol; Sevoflurane; Triamcinolone Acetonide | |||
25 March 2013 | Effective Date of Requirement for Premarket Approval for Automated External Defibrillator System | |||
25 March 2013 | Determination That BENADRYL (diphenhydramine hydrochloride) Injection and Two Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness | |||
25 March 2013 | Accessible Medical Device Labeling in a Standard Content and Format Public Workshop; Extension of Comment Period | |||
26 March 2013 | Service of Process on Manufacturers; Manufacturers Importing Electronic Products Into the United States; Agent Designation; Change of Address | |||
26 March 2013 | Medical Devices; Technical Amendment | |||
26 March 2013 | Food Labeling; Notification Procedures for Statements on Dietary Supplements | |||
26 March 2013 | Determination That QUESTRAN (Cholestyramine for Oral Suspension, USP), Equivalent to 4 Grams, and QUESTRAN LIGHT (Cholestyramine for Oral Suspension, USP), Equivalent to 4 Grams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness | |||
26 March 2013 | Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility; Availability | |||
27 March 2013 | Summit on Color in Medical Imaging; Cosponsored Public Workshop; Request for Comments | |||
27 March 2013 | Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 | |||
28 March 2013 | Guidance for Industry and Food and Drug Administration Staff: Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi | |||
29 March 2013 | Draft Guidance for Industry on Bioequivalence Recommendations for Metronidazole Vaginal Gel | |||
1 April 2013 | Listing of Color Additives Exempt From Certification; Reactive Blue 246 and Reactive Blue 247 Copolymers | |||
1 April 2013 | Draft Guidance for Industry on Formal Meetings Between FDA and Biosimilar Biological Product Sponsors or Applicants | |||
1 April 2013 | Draft Guidance for Industry on Scale-Up and Post-Approval Changes: Manufacturing Equipment Addendum | |||
2 April 2013 | Change of Address; Biologics License Applications; Technical Amendment | |||
2 April 2013 | Center for Devices and Radiological Health: Experiential Learning Program | |||
2 April 2013 | Guidance for Industry and Food and Drug Administration Staff: User Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications | |||
2 April 2013 | Implementation of the FDA Food Safety Modernization Act Provision Requiring FDA To Establish Pilot Projects and Submit a Report to Congress for the Improvement of Tracking and Tracing of Food; Extension of Comment Period | |||
2 April 2013 | International Consortium of Cardiovascular Registries | |||
2 April 2013 | Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee: Notice of Change of Meeting Schedule | |||
2 April 2013 | Modifications To Labeling of Nicotine Replacement Therapy Products for Over-the-Counter Human Use | |||
2 April 2013 | New Animal Drugs; Enrofloxacin; Tilmicosin; Tylosin | |||
3 April 2013 | Information To Accompany Humanitarian Device Exemption Applications and Annual Distribution Number Reporting Requirements | |||
3 April 2013 | Draft Guidance for Industry and Food and Drug Administration Staff; Glass Syringes for Delivering Drug and Biological Products: Technical Information To Supplement International Organization for Standardization Standard 11040-4 | |||
3 April 2013 | Effective Date of Requirement for Premarket Approval for Three Class III Preamendments Devices; Reclassification of Sorbent Hemoperfusion Devices for the Treatment of Poisoning and Drug Overdose | |||
4 April 2013 | 2013 Parenteral Drug Association/Food and Drug Administration Joint Regulatory Conference: Driving Quality and Compliance Throughout the Product Life Cycle in a Global Regulatory Environment | |||
4 April 2013 | Draft Compliance Policy Guide Sec. 100.250 Food Facility Registration-Human and Animal Food | |||
4 April 2013 | Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee; Amendment of Notice | |||
4 April 2013 | Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee: Notice of Postponement of Meeting | |||
4 April 2013 | Peripheral and Central Nervous System Drugs Advisory Committee | |||
5 April 2013 | Agreement for Shipment of Devices for Sterilization | |||
5 April 2013 | Export of Medical Devices; Foreign Letters of Approval | |||
5 April 2013 | 2013 Medical Countermeasures Initiative Regulatory Science Symposium | |||
5 April 2013 | Society of Clinical Research Associates-Food and Drug Administration: Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice | |||
5 April 2013 | Vaccines and Related Biological Products Advisory Committee | |||
5 April 2013 | Pediatric Device Consortia Grant Program | |||
5 April 2013 | Food and Drug Administration/National Institutes of Health/National Science Foundation Public Workshop on Computer Methods for Medical Devices | |||
8 April 2013 | Center for Biologics Evaluation and Research eSubmitter Pilot Evaluation Program for Investigational New Drug Applications | |||
8 April 2013 | Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations | |||
8 April 2013 | Draft Guidance for Industry on Providing Postmarket Periodic Safety Reports in the International Conference on Harmonisation E2C(R2) Format (Periodic Benefit-Risk Evaluation Report) | |||
8 April 2013 | Center for Devices and Radiological Health: Health of Women Program | |||
9 April 2013 | New Animal Drugs; Change of Sponsor | |||
9 April 2013 | Establishment of a Public Docket for Administrative Detention Under the Food and Drug Administration Safety and Innovation Act | |||
9 April 2013 | Draft Guidance for Industry and Food and Drug Administration Staff: Molecular Diagnostic Instruments With Combined Functions | |||
11 April 2013 | Guidance for Industry on Self-Selection Studies for Nonprescription Drug Products | |||
11 April 2013 | Guidance for Industry and Food and Drug Administration Staff: Medical Device Classification Product Codes | |||
11 April 2013 | Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013-2015 | |||
15 April 2013 | International Conference on Harmonisation; Draft Guidance on M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk | |||
15 April 2013 | Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee | |||
16 April 2013 | Generic Drug Facilities, Sites, and Organizations | |||
16 April 2013 | Document to Support Submission of an Electronic Common Technical Document-Specifications for File Format Types Using Electronic Common Technical Document Specifications | |||
17 April 2013 | Guidance for Industry on Non-Penicillin Beta-Lactam Drugs: A Current Good Manufacturing Practices Framework for Preventing Cross-Contamination | |||
18 April 2013 | Determination That the OXYCONTIN (Oxycodone Hydrochloride) Drug Products Covered by New Drug Application 20-553 Were Withdrawn From Sale for Reasons of Safety or Effectiveness | |||
18 April 2013 | Guidance for Industry on Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims | |||
19 April 2013 | Use of Certain Symbols in Labeling | |||
19 April 2013 | Clinical Laboratory Improvement Amendments Waiver Applications | |||
19 April 2013 | Electronic Submission of Medical Device Registration and Listing | |||
19 April 2013 | Guidance for Industry, FDA Staff, and Foreign Governments: Fiscal Year 2012 Medical Device User Fee Small Business Qualification and Certification | |||
19 April 2013 | Health Care Professional Survey of Prescription Drug Promotion | |||
23 April 2013 | Investigational Device Exemptions Reports and Records | |||
23 April 2013 | Annual Public Meeting of Reagan-Udall Foundation | |||
23 April 2013 | Draft Guidance for Industry and Food and Drug Administration Staff: Use of International Standard ISO-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing" | |||
23 April 2013 | Pilot Program for Early Feasibility Study Investigational Device Exemption Applications; Extending the Duration of the Program | |||
24 April 2013 | Protection of Human Subjects: Informed Consent; Institutional Review Boards | |||
23 April 2013 | Experimental Study: Examination of Corrective Direct-to-Consumer Television Advertising | |||
24 April 2013 | Draft Guidance for Industry on Safety Considerations for Container Labels and Carton Labeling Design To Minimize Medication Errors | |||
25 April 2013 | Guidance for Industry and Food and Drug Administration Staff: Assay Migration Studies for In Vitro Diagnostic Devices | |||
25 April 2013 | Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee | |||
26 April 2013 | Guidance for Industry on Regulatory Classification of Pharmaceutical Co-Crystals | |||
30 April 2013 | New Animal Drugs; Dexmedetomidine; Lasalocid; Melengestrol; Monensin; and Tylosin | |||
30 April 2013 | Abbreviated New Animal Drug Applications | |||
1 May 2013 | Guidance: Emergency Use Authorization of Medical Products | |||
1 May 2013 | Medical Devices; Inspection by Accredited Persons Program | |||
1 May 2013 | Ashley Brandon Foyle: Debarment Order | |||
2 May 2013 | Product Jurisdiction: Assignment of Agency Component for Review of Premarket Applications | |||
2 May 2013 | Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee | |||
2 May 2013 | Submission of New Drug Application/Abbreviated New Drug Application Field Alert Reports: Notice of Form FDA 3331-Automated Pilot Program | |||
6 May 2013 | Electronic Submission Process for Voluntary Complaints to the Center for Devices and Radiological Health | |||
6 May 2013 | An Evaluation of the Prescription Drug User Fee Act Workload Adjuster | |||
6 May 2013 | Food and Drug Administration/International Society for Pharmaceutical Engineering Co-Sponsorship Educational Workshop: Redefining the `C' in CGMP (Current Good Manufacturing Practices): Creating, Implementing, and Sustaining a Culture of Quality | |||
8 May 2013 | Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Act | |||
8 May 2013 | Public Health Service Guideline on Infectious Disease Issues on Xenotransplantation | |||
8 May 2013 | David Freeman: Debarment Order | |||
8 May 2013 | Guidance for Industry: Implementation of an Acceptable Abbreviated Donor History Questionnaire and Accompanying Materials for Use in Screening Frequent Donors of Blood and Blood Components | |||
8 May 2013 | 510(k) Device Modifications: Deciding When To Submit a 510(k) for a Change to an Existing Device; Public Meeting | |||
8 May 2013 | Microbiology Devices Panel of the Medical Devices Advisory Committee | |||
9 May 2013 | General and Plastic Surgery Devices: Reclassification of Ultraviolet Lamps for Tanning, Henceforth To Be Known as Sunlamp Products | |||
9 May 2013 | Draft Guidance for Industry on Charging for Investigational Drugs Under an Investigational New Drug Application-Questions and Answers | |||
9 May 2013 | Draft Guidance for Industry on Expanded Access to Investigational Drugs for Treatment Use-Questions and Answers | |||
9 May 2013 | Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives Public Hearing | |||
10 May 2013 | Applications for Food and Drug Administration Approval To Market a New Drug; Postmarketing Reports; Reporting Information About Authorized Generic Drugs | |||
10 May 2013 | Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens That Are Not Individually Identifiable | |||
10 May 2013 | Anesthetic and Analgesic Drug Products Advisory Committee | |||
13 May 2013 | New Animal Drugs; Change of Sponsor's Name and Address; Change of Sponsor | |||
13 May 2013 | New Animal Drug Applications and Supporting Regulations and Form FDA 356V | |||
13 May 2013 | Determination That REV-EYES (Dapiprazole Hydrochloride Ophthalmic Solution), 0.5%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | |||
13 May 2013 | Dental Products Panel of the Medical Devices Advisory Committee | |||
14 May 2013 | Communicating Composite Scores in Direct-to-Consumer Advertising | |||
14 May 2013 | Prescription Drug Product Labeling; Medication Guide Requirements | |||
14 May 2013 | Guidance for Industry and Food and Drug Administration Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data | |||
16 May 2013 | Medical Devices; General Hospital and Personal Use Monitoring Devices; Classification of the Ingestible Event Marker | |||
16 May 2013 | Guidance for Industry on How To Submit Information in Electronic Format to Center for Veterinary Medicine Using the Food and Drug Administration's Electronic Submission Gateway | |||
16 May 2013 | Bar Code Label Requirement for Human Drug and Biological Products | |||
16 May 2013 | Postmarket Surveillance | |||
17 May 2013 | Guidance for Industry and FDA Staff: Center for Devices and Radiological Health Appeals Processes | |||
17 May 2013 | Center for Devices and Radiological Health Appeals Processes: Questions and Answers About 517A; Draft Guidance for Industry and Food and Drug Administration Staff | |||
17 May 2013 | Anesthetic and Analgesic Drug Products Advisory Committee | |||
21 May 2013 | Human Immunodeficiency Virus Patient-Focused Drug Development and Human Immunodeficiency Virus Cure Research | |||
21 May 2013 | Cardiovascular Devices: Reclassification of External Counter-Pulsating Devices for Treatment of Chronic Stable Angina, etc. | |||
22 May 2013 | Standardizing and Evaluating Risk Evaluation and Mitigation Strategies | Meeting | ||
22 May 2013 | Oral Dosage Form New Animal Drugs: Clindamycin; Enrofloxacin | |||
22 May 2013 | Meetings: Science Board to the Food and Drug Administration | Meeting | ||
22 May 2013 | Requests for Clinical Laboratory Improvement Amendments Categorization | |||
23 May 2013 | Drug Safety and Risk Management Advisory Committee | Meeting | ||
23 May 2013 | General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee | Meeting | ||
28 May 2013 | International Conference on Harmonisation Guidance; Availability: Q4B Evaluation and Recommendation of Pharmacopoeial Texts; Annex 13 on Bulk Density and Tapped Density of Powders | |||
28 May 2013 | Draft Guidance for Industry; Availability: Contract Manufacturing Arrangements for Drugs; Quality Agreements | |||
28 May 2013 | Clinical Development Programs for Opioid Conversion | Meeting | ||
30 May 2013 | Requirements for Submission of Labeling for Human Prescription Drugs and Biologics in Electronic Format | |||
30 May 2013 | Arthritis Advisory Committee | Meeting | ||
30 May 2013 | Food and Drug Administration Safety and Innovation Act (FDASIA): Request for Comments on the Development of a Risk-Based Regulatory Framework and Strategy for Health Information Technology | |||
31 May 2013 | Draft Guidance for Industry; Availability: Rheumatoid Arthritis; Developing Drug Products for Treatment | |||
31 May 2013 | Draft Guidance for Industry: Changes to an Approved Application; Biological Products, Human Blood and Blood Components Intended for Transfusion, etc. | |||
31 May 2013 | New Approaches to Antibacterial Drug Development | |||
4 June 2013 | New Drug Applications; Approval Withdrawals: ORAFLEX; Eli Lilly and Co. | |||
4 June 2013 | Arthritis Advisory Committee | Meeting | ||
4 June 2013 | Masked and De-identified Non-Summary Safety and Efficacy Data |